ID   MZ-MEL-2
AC   CVCL_1435
SY   Mz-Mel-2; MZ Mel 2; MZ-2 Mel; MZ2-MEL; MZ2-Mel; MZ2-mel; MZ2MEL
DR   CLO; CLO_0037132
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_1435
DR   Cell_Model_Passport; SIDM00179
DR   ChEMBL-Cells; CHEMBL3308272
DR   ChEMBL-Targets; CHEMBL2366226
DR   Cosmic; 971777
DR   Cosmic-CLP; 971777
DR   DepMap; ACH-002165
DR   EGA; EGAS00001000978
DR   GDSC; 971777
DR   GEO; GSM1507939
DR   GEO; GSM1670140
DR   IARC_TP53; 27565
DR   LINCS_LDP; LCL-1278
DR   PharmacoDB; MZ2MEL_976_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1435
DR   Wikidata; Q54907223
RX   PubMed=2529220;
RX   PubMed=3972469;
RX   PubMed=8509230;
RX   PubMed=8566071;
RX   PubMed=9637538;
RX   PubMed=20164919;
RX   PubMed=25502142;
RX   PubMed=25728708;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=25728708; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 9829; RAF1; Simple; p.Ser257Leu (c.770C>T); ClinVar=VCV000013957; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0.15%; East Asian, North=0.41%; East Asian, South=0.66%; South Asian=0.41%; European, North=64.57%; European, South=33.8% (PubMed=30894373).
CC   Derived from site: Metastatic; Abdomen; UBERON=UBERON_0000916.
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 12
ST   D16S539: 12,13
ST   D5S818: 9,11
ST   D7S820: 10,12
ST   TH01: 8,9.3
ST   TPOX: 8,12
ST   vWA: 16,18
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C5U5 ! MZ2-EBV
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 34
//
RX   PubMed=2529220; DOI=10.1002/ijc.2910440413;
RA   van den Eynde B.J., Hainaut P., Herin M., Knuth A., Lemoine C.,
RA   Weynants P., van der Bruggen P., Fauchet R., Boon T.;
RT   "Presence on a human melanoma of multiple antigens recognized by
RT   autologous CTL.";
RL   Int. J. Cancer 44:634-640(1989).
//
RX   PubMed=3972469; DOI=10.1002/ijc.2910350215;
RA   Vessiere-Louveaux F.M.Y.R., Darville M., Knuth A., Boon T.;
RT   "Use of irradiated mouse fibroblasts to improve the cloning and
RT   adaptation to culture of human melanoma cells.";
RL   Int. J. Cancer 35:231-235(1985).
//
RX   PubMed=8509230; DOI=10.1002/ijc.2910540329;
RA   Rimoldi D., Romero P., Carrel S.;
RT   "The human melanoma antigen-encoding gene, MAGE-1, is expressed by
RT   other tumour cells of neuroectodermal origin such as glioblastomas and
RT   neuroblastomas.";
RL   Int. J. Cancer 54:527-528(1993).
//
RX   PubMed=8566071; DOI=10.1002/eji.1830260135;
RA   Brichard V.G., Herman J., Van Pel A., Wildmann C., Gaugler B.,
RA   Wolfel T., Boon T., Lethe B.;
RT   "A tyrosinase nonapeptide presented by HLA-B44 is recognized on a
RT   human melanoma by autologous cytolytic T lymphocytes.";
RL   Eur. J. Immunol. 26:224-230(1996).
//
RX   PubMed=9637538; DOI=10.4049/jimmunol.160.12.6188;
RA   Gueguen M., Patard J.-J., Gaugler B., Brasseur F., Renauld J.-C.,
RA   Van Cangh P.J., Boon T., van den Eynde B.J.;
RT   "An antigen recognized by autologous CTLs on a human bladder
RT   carcinoma.";
RL   J. Immunol. 160:6188-6194(1998).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=25502142; DOI=10.1038/ncomms6712;
RA   Muller J., Krijgsman O., Tsoi J., Robert L., Hugo W., Song C.,
RA   Kong X.-J., Possik P.A., Cornelissen-Steijger P.D.M., Geukes Foppen M.H.,
RA   Kemper K., Goding C.R., McDermott U., Blank C., Haanen J.B.A.G.,
RA   Graeber T.G., Ribas A., Lo R.S., Peeper D.S.;
RT   "Low MITF/AXL ratio predicts early resistance to multiple targeted
RT   drugs in melanoma.";
RL   Nat. Commun. 5:5712.1-5712.15(2014).
//
RX   PubMed=25728708; DOI=10.1111/pcmr.12364;
RA   Vogel C.J., Smit M.A., Maddalo G., Possik P.A., Sparidans R.W.,
RA   van der Burg S.H., Verdegaal E.M.E., Heck A.J.R., Samatar A.A.,
RA   Beijnen J.H., Altelaar A.F.M., Peeper D.S.;
RT   "Cooperative induction of apoptosis in NRAS mutant melanoma by
RT   inhibition of MEK and ROCK.";
RL   Pigment Cell Melanoma Res. 28:307-317(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//